Johnson & Johnson's single-dose coronavirus vaccine just got one step closer to reaching the public, as US regulators released documents showing the shot was safe and confirming that it can help prevent COVID-19.
One simple chart in the FDA's review shows a key takeaway from J&J's study: the vaccine works quite well, leading to far fewer COVID-19 cases among volunteers who received the shot.
J&J's efficacy figures are markedly lower than the 94% and 95% efficacy rates shown by two-dose vaccines from Moderna and Pfizer, but it's difficult to directly compare the studies, as they happened at different stages in the pandemic and across different geographies.
Expect a debate among experts in the coming days over just how much the efficacy difference matters. Stay up to date with how it all happens by subscribing to @BusinessInsider.
